| GLYCOPYRROLATE; INDACATEROL MALEATE | None | ||
| 0.0156MG;0.0275MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| UTIBRON NEOHALER is a combination of indacaterol, a long-acting beta2adrenergic agonist (LABA), and glycopyrrolate, an anticholinergic, indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). | |||
|
Yes
| |||
| UTIBRON NEOHALER | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||
| *** ****** *********** ********** **-*** ****** ********* *** ********* ********** | ******* ****** | ******* ********* *** *** ** *** ****** ******** | ******* ********* *** *** ** *** ****** ******** | ****-*-************** ******** | ****-*-************** ******** | ****-*-************** ******** | *****-************** ******** | *****-************** ******** | ********* ** *********** ******* | ********* ** *********** ******** | ****** ** ****** ********* *** *** ** * ************** *********** | ************** ************ *** ********** | ****** ** ****** ********* *** *** ** * ************** *********** | ************** ************ ** *********** *******-******** ****** ********* ************** *** ********** | ********* *** *** ** * ************** *********** | ****** ** ****** ********* ********* *** *** ** ************** ************ *** ********* ********* *** ************ ******* | ****** ** ****** ********* *** *** ** * ************** *********** | ****** ** ****** ********* *** *** ** * ************** *********** | *****-************ ******** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|